entertainment -WSS

entertainment

author：explore 2025-10-01 04:13:27 - browse：6566

Rod Nathan, Ali Urman, and Patrick Nosker on the 2024 Breakthrough Summit East stage. — From left, Rod Nathan, portfolio manager and partner of J. Goldman & Co.; ARK Invest senior analyst Ali Urman; and Patrick Nosker, director of research and partner at Affinity Asset Advisors, discuss biotech investment opportunities at the 2024 STAT Breakthrough Summit East. STAT

Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on the horizon.

Driving the momentum? Economics 101.

Biotechs rely on borrowing capital, which is a more tenuous task when interest rates are high. But interest rates have most likely peaked, with Federal Reserve officials signaling earlier this week they expected to make three cuts this year. For public biotechnology startups that have been battered by the market in recent years, this is a very good thing, Rod Nathan, portfolio manager and partner of J. Goldman & Co., said on a panel at STAT’s Breakthrough Summit East in New York on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Let's speed up science by embracing open access publishing

entertainment

hotspot

WSS

Biden White House, tech companies launch new safeguards around emerging AI technology

Florida babysitter arrested over hot car death, authorities say

Shifting the focus from loneliness to social health

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Letters to First Opinion on caregivers, digital health, and more

entertainment

entertainment

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Change Healthcare can notify patients about the breach, HHS says

Affirmative action in medical school literally saved lives

Reframing the conversation around gain

Supreme Court strikes down use of affirmative action

EMA weighs against approval for Mirati's lung cancer drug

23andMe had bad news about my health. I wish a person had delivered it

Biden White House, tech companies launch new safeguards around emerging AI technology

ChatGPT in medicine: STAT answers readers' burning questions

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

knowledge

How Brent Saunders' Allergan experiment failed

A former Republican legislative candidate has been charged for his role in the US Capitol riot

HIV drugs protect against transmission, even in unprotected sex

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

EMA weighs against approval for Mirati's lung cancer drug

Let's speed up science by embracing open access publishing

entertainment

hotspot

hotspot

knowledge